Morgan Stanley Lifts Price Target on Edwards Lifesciences to $103 From $95, Sees 'Upside Risk' Amid Transcatheter Mitral & Tricuspid Therapies, Overweight Rating Kept
Morgan Stanley Lifts Price Target on Edwards Lifesciences to $103 From $95, Sees 'Upside Risk' Amid Transcatheter Mitral & Tricuspid Therapies, Overweight Rating Kept
摩根士丹利將愛德華茲生命科學的目標股價從95美元上調至103美元，在經導管二尖瓣和三尖瓣療法中看到 “上行風險”，增持評級保持不變
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊